Biomedicine & Pharmacotherapy · 2024 · 23 citations · 37 references
MedicineCancer BiologyPharmacologyCancer PharmacologyGene ExpressionTumor ProgressionCancer Cell SignalingCancer Stem CellsCancer TranscriptomicsOncogenic Signaling PathwaysTargeted Cancer TherapyTargeted TherapyBiological ValidationDna Damage InductionGene Regulatory InteractionsParp InhibitionPhosphatidylinositol 3-Kinase-akt PathwayPi3k-akt Signaling PathwayTumor Suppression MechanismsTumor Suppression Pathways
-methyladenosine (m6A) regulator METTL3 is an important regulatory gene in various progressive processes of prostate cancer (PCa). METTL3 inhibitors have been reported to possess potent tumor suppression capacity in some cancer types. Nevertheless, the detailed influence and mechanism of METTL3 inhibitors on PCa progression and their potential synergy with other drugs are poorly understood. In this study, we demonstrated that METTL3 was overexpressed and associated with poor survival in most PCa patients. METTL3 inhibitor STM2457 reduced m6A levels of PCa cells, thus inhibiting their proliferation, colony formation, migration, invasion, and stemness in vitro. Furthermore, STM2457 suppressed PCa progression in both the CDX and PDX models in vivo. MeRIP-seq analysis coupled with biological validation revealed that STM2457 influenced multiple biological processes in PCa cells, mainly through the IGFBP3/AKT pathway. We also proved that STM2457 induced DNA damage and showed synergistic anti-PCa effects with the PARP inhibitor olaparib both in vitro and in vivo. All in all, this work provides a novel therapeutic strategy for targeting RNA m6A modifications for the treatment of PCa and provides a meaningful reference for further clinical trials.
37
Rebecca L. Siegel, Angela N. Giaquinto, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2024 · 9K citations · Full text
Medicine, Oncology, Cancer Control +16
N6-methyladenosine-dependent regulation of messenger RNA stability
Xiao Wang, Zhike Lu, Adrian Gomez-Nguyen et al. · Nature · 2013 · 4.8K citations
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.2K citations · Full text